NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port efficacy with microchip and sensor technology, NGP measures, monitors and reports physiological body functions in vivo over the course of disease and treatment.
In this episode, Founder and CEO Kathy Skinner shares the details of how this port advances care for a very important patient population and how its quickly gaining momentum.
Julie Anderson is the Director of Strategic Initiatives at Cambia Grove and a healthcare veteran.Cambia Grove is a health care innovation hub focused on...
Lactiga is a venture-backed, NIH-funded biotherapeutics company developing patented biologics to treat and prevent mucosal infections with a focus on improving the quality of...
Petra Capital Properties is a mission-based real estate investment management company dedicated to serving their clients with high quality real estate investment opportunities with...
